LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Center
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • CDMO Service
      • Core Value
      • Manufacturing
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
    • LUCATREE Advanced Regenerative Medicine
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries

Quantity of Cord Blood under Custody Exceeds 200,000 Units for the First Time in Korea

2015/01/27
CORD BLOOD BANK

MEDIPOST achieved 200,000 units of cord blood under custody for the first time in Korea.

This number is similar to the level under custody by major advanced countries such as U.S. Europe and Japan etc., accounting for 40% of whole domestic cord blood units under custody.

MEDIPOST started cord blood custody service opening Celltree cord blood bank in December 2000, and achieved this grand record in 14 years.

MEDIPOST is keeping the number one market share by widest margin among 17 domestic cord blood banks, in custody of over 15,000 units for recent 3 consecutive years.

MEDIPOST obtained modern facilities such as automatic nitrogen recharge system under central control and internally developed portable cord blood custody tank etc., at its own building located at Pangyo Techno Valley. And remarkably enhanced confidence and stability of cord blood custody.

VIEW LIST

Related News

news 200518
Star Actress Choi Jiwoo Stores Her Baby’s Umbilical Cord Blo…
2020/05/18
news 180108
Longer-Term Storage of Cord Blood Gains Popularity Over 20,0…
2020/04/29

Latest News

knee img
MEDIPOST Inc. Treats First U.S. Participant in Phase III Tri…
2026/07/07
cdmo img33
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Stu…
2026/06/04
news
MEDIPOST’s CARTISTEM® Meets All Primary and Secondary…
2026/05/13
medipost img 2
MEDIPOST, INC. ANNOUNCES $140 MILLION IN FUNDING TO ACCELERA…
2026/01/09
knee img
MEDIPOST Inc. Treats First U.S. Participant in Phase III Tri…
2026/07/07
cdmo img33
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Stu…
2026/06/04
news
MEDIPOST’s CARTISTEM® Meets All Primary and Secondary…
2026/05/13
medipost img 2
MEDIPOST, INC. ANNOUNCES $140 MILLION IN FUNDING TO ACCELERA…
2026/01/09

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

Latest News

MEDIPOST Inc. Treats First U.S. Particip…2026.07.07
MEDIPOST Secures FDA Agreement on Single…2026.06.04
MEDIPOST’s CARTISTEM® Meets All Pr…2026.05.13
MEDIPOST, INC. ANNOUNCES $140 MILLION IN…2026.01.09
MEDIPOST Announces the Exclusive Commerc…2025.12.19

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST